The appointment covers media planning and buying in the US for Novo Nordisk, whose portfolio includes blockbuster diabetes and weight-loss brands Ozempic and Wegovy. The account is understood to be one of the year's most closely watched media pitches, given the rapid growth of the GLP-1 market and Novo Nordisk's sizeable advertising investment.
The move represents another setback for WPP, which has been under pressure amid a series of account reviews and client changes globally. Novo Nordisk's decision follows a competitive process that saw Omnicom emerge as the successful bidder for the US business.
